Gozde Yildirim, Edmara T P Bergamo, Sher Bahadur Poudel, Ryan R Ruff, Manisha Dixit, Bin Hu, Dindo Q Mijares, Lukasz Witek, Carolyn Chlebek, David E Harrison, Randy Strong, Richard A Miller, Warren Ladiges, Timothy G Bromage, Clifford J Rosen, Shoshana Yakar
Sodium glucose cotransporter-2 inhibitors (SGLT2is) promote urinary glucose excretion and decrease plasma glucose levels independent of insulin. Canagliflozin (CANA) is an SGLT2i, which is widely prescribed, to reduce cardiovascular complications, and as a second-line therapy after metformin in the treatment of type 2 diabetes mellitus. Despite the robust metabolic benefits, reductions in bone mineral density (BMD) and cortical fractures were reported for CANA-treated subjects. In collaboration with the National Institute on Aging (NIA)-sponsored Interventions Testing Program (ITP), we tested skeletal integrity of UM-HET3 mice fed control (137 mice) or CANA-containing diet (180 ppm, 156 mice) from 7 to 22 months of age...
May 11, 2023: GeroScience